• Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators, F Van De Werf, J Adgey, D Ardissino, P W Armstrong, P Aylward, G Barbash, A Betriu, A S Binbrek, R Califf, R Diaz, R Fanebust, K Fox, C Granger, J Heikkilä, S Husted, P Jansky, A Langer, E Lupi, A Maseri, J Meyer, J Mlczoch, D Mocceti, D Myburgh, A Oto, E Paolasso, K Pehrsson, R Seabra-Gomes, L Soares-Piegas, D Sùgrue, M Tendera, E Topol, P Toutouzas, A Vahanian, F Verheugt, L Wallentin, and H White.
• Lancet. 1999 Aug 28; 354 (9180): 716-22.

BackgroundBolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a genetically engineered variant of alteplase with slower plasma clearance, better fibrin specificity, and high resistance to plasminogen-activator inhibitor-1. We did a double-blind, randomised, controlled trial to assess the efficacy and safety of tenecteplase compared with alteplase.MethodsIn 1021 hospitals, we randomly assigned 16,949 patients with acute myocardial infarction of less than 6 h duration rapid infusion of alteplase (< or = 100 mg) or single-bolus injection of tenecteplase (30-50 mg according to bodyweight). All patients received aspirin and heparin (target activated partial thromboplastin time 50-75 s). The primary outcome was equivalence in all-cause mortality at 30 days.FindingsCovariate-adjusted 30-day mortality rates were almost identical for the two groups--6.18% for tenecteplase and 6.15% for alteplase. The 95% one-sided upper boundaries of the absolute and relative differences in 30-day mortality were 0.61% and 10.00%, respectively, which met the prespecified criteria of equivalence (1% absolute or 14% relative difference in 30-day mortality, whichever difference proved smaller). Rates of intracranial haemorrhage were similar (0.93% for tenecteplase and 0.94% for alteplase), but fewer non-cerebral bleeding complications (26.43 vs 28.95%, p=0.0003) and less need for blood transfusion (4.25 vs 5.49%, p=0.0002) were seen with tenecteplase. The rate of death or non-fatal stroke at 30 days was 7.11% with tenecteplase and 7.04% with alteplase (relative risk 1.01 [95% CI 0.91-1.13]).InterpretationTenecteplase and alteplase were equivalent for 30-day mortality. The ease of administration of tenecteplase may facilitate more rapid treatment in and out of hospital.

17 keywords...

hide…